Bikash khadka | Medicine and Dentistry | Best Researcher Award

Posted on 10/12/202410/12/2024 by ScienceFather

Dr. Bikash khadka | Medicine and Dentistry | Best Researcher Award

Dr. Bikash khadka , Nepal Mediciti , Nepal

Dr. Bikash Khadka is a dedicated anesthesiologist from Lalitpur, Kathmandu, Nepal, with extensive experience in critical care and perioperative medicine. He earned his MD in Anesthesiology from Lumbini Medical College, affiliated with Kathmandu University, in 2018, after completing his MBBS at Kathmandu University School of Medical Sciences in 2012. Dr. Bikash Khadka currently serves as a Junior Consultant Anesthesiologist at Nepal Mediciti Hospital, where he manages a 32-bed mixed ICU and conducts anesthesia for various surgeries. Passionate about medical education, he has also served as a Lecturer at Lumbini Medical College. His research focuses on anesthesia techniques, critical care, and perioperative safety, with numerous published articles in peer-reviewed journals. He is proficient in advanced airway management, regional blocks, and critical patient care. Dr. Bikash Khadka actively participates in medical workshops and conferences to stay updated in his field.

Publication Profile

Scopus

Work Experience

Dr. Bikash Khadka has been a Junior Consultant Anesthesiologist at Nepal Mediciti Hospital since August 2019, where he manages a 32-bed mixed ICU and provides anesthesia for diverse surgeries. From November 2018 to August 2019, he worked as a Lecturer at Lumbini Medical College, teaching anesthesiology to medical students. As a Resident Doctor (2015-2018) at the same institution, he performed pre-anesthetic assessments, anesthesia conduction, ICU management, and supervised junior residents. His responsibilities included emergency surgeries, obstetric analgesia, and critical care. From September 2013 to March 2014, he was a Medical Officer at Alka Hospital, providing emergency care. His experience spans specialized anesthesia services, resuscitation, and managing patients across various surgical and ICU settings.

Education and Training

Dr. Bikash Khadka earned his MD in Anesthesiology from Lumbini Medical College, affiliated with Kathmandu University, from 2015 to 2018. Prior to that, he completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) at Kathmandu University School of Medical Sciences between 2008 and 2012. During his medical education, he acquired extensive theoretical knowledge and hands-on experience, laying the foundation for his career in anesthesiology and critical care. His education focused on pre-anesthetic assessment, anesthesia conduction, ICU management, and patient care during complex surgical procedures. Dr. Bikash Khadka also completed significant training, including ACLS, BLS, airway management, and acute care ultrasound workshops, strengthening his proficiency in both clinical and emergency care. His commitment to continual learning is reflected in his active participation in national conferences and specialized courses.

Awards and Training

Dr. Bikash Khadka has attended various prestigious conferences and workshops, including the 17th National Conference of the Society of Anesthesiologists of Nepal (SANCON) in 2016. He participated in specialized workshops like the Difficult Airway Workshop and Acute Care Ultrasound Workshop. He holds certifications in Advanced Cardiovascular Life Support (ACLS) and Basic Life Support (BLS), showcasing his dedication to critical care excellence. His commitment to academic excellence is evident through his lecturer role and involvement in training junior residents. Dr. Bikash Khadka’s clinical expertise and research contributions have established him as a respected professional in anesthesiology and critical care in Nepal.

Research Focus

Dr. Bikash Khadka’s research focuses on anesthesiology, critical care, and perioperative management. His interests include optimizing patient outcomes in ICU settings, managing complex airway cases, and preventing anesthesia-related complications. He has contributed to research on rare medical conditions, such as Boerhaave syndrome and post-COVID-19 vaccine complications. Dr. Bikash khadka is also interested in comparative studies on pharmacological agents to improve surgical outcomes, such as using dexmedetomidine and dexamethasone for postoperative nausea prevention. His work often explores innovative approaches to regional anesthesia, patient safety, and critical care protocols. His systematic reviews and case reports provide valuable insights into anesthesia practice and patient management.

Publication Top Notes

Role of pre-operative counseling with NSQIP surgical risk calculator in the surgical patients

Authors: Khadka, B., Sharma, A., Bhattarai, P.R., Rayamajhi, B., Adhikari, H.

Journal: Surgery Open Science

Year: 2024

Volume: 18, pp. 11–16

Citations: 0

Pyopericardium progressing to cardiac tamponade in a patient with dengue fever

Authors: Khadka, B., Khanal, K., Regmi, A., KC, S., Nepal, R.

Journal: IDCases

Year: 2024

Volume: 36, Article e01996

Citations: 0

Removing knotted or stuck epidural catheters: a systematic review of case reports

Authors: Khadka, B., Sharma, A., Regmi, A., Ghimire, A., Bhattarai, P.R.

Journal: Anesthesia and Pain Medicine

Year: 2023

Volume: 18(3), pp. 315–324

Citations: 1

A rare case of Boerhaave syndrome with cervico-thoracic esophageal junction rupture causing bilateral empyema; case report from Nepal

Authors: Khadka, B., Khanal, K., Dahal, P., Adhikari, H.

Journal: International Journal of Surgery Case Reports

Year: 2023

Volume: 105, Article 108018

Citations: 2

Post COVID-19 vaccine Guillain-Barré syndrome

Authors: Khadka, B., Khanal, K.

Journal: Journal of Nepal Health Research Council

Year: 2022

Volume: 19(4), pp. 852–854

Citations:

Tiantian Zhang | Health Professions | Best Researcher Award

Posted on 02/12/202402/12/2024 by ScienceFather

Dr. Tiantian Zhang | Health Professions | Best Researcher Award

Dr. Tiantian Zhang, Fudan University, China

Dr. Tiantian Zhang is a dedicated researcher in the field of public health, specializing in the construction of public health systems and proactive health technologies within the context of medical health big data. Currently serving as a Youth Researcher at the School of Public Health at Fudan University since October 2023, she brings an academic background with a Master’s and Doctorate in Management, focusing on social medicine and health management from Fudan University. She has contributed significantly to over 38 publications, with many in high-impact journals, particularly in health policy, public health emergency responses, and chronic disease prevention. Her research also covers the intersection of technology, public health, and healthcare systems. She has been involved in various research projects and has received substantial funding for her work. Dr. Zhang’s academic journey includes postdoctoral research and entrepreneurial experience in management science and data science. Additionally, she is a key member of national projects on public health and disease prevention.

Publication Profile

Scopus

Academic Background 🎓📚

Dr. Tiantian Zhang pursued her graduate studies at Fudan University, where she earned a Master’s degree in Management with a focus on Social Medicine and Health Administration from September 2016 to June 2018. 🏫🎓 She continued her academic journey at Fudan, completing a PhD in Management in the same field from June 2018 to June 2021. 🔬 Her doctoral research contributed to advancing public health management and policy, further establishing her expertise in healthcare systems and social medicine. Dr. Zhang’s academic foundation laid the groundwork for her current work in public health and health data research. 🌟📊

Professional and Visiting Scholar Experience 💼🌍

Dr. Tiantian Zhang has held various esteemed positions in her career. Since October 2023, she has been serving as a Youth Researcher at Fudan University, focusing on Health Management. 🏫🧑‍🔬 From June 2021 to September 2023, she worked as a Postdoctoral Researcher at Fudan University, specializing in Public Policy. 📜🔍 Additionally, since September 2017, Dr. Zhang has been the founder and legal representative of Shanghai Haiyu Information Technology Co., Ltd., where she applies her expertise in Management Science and Data Science. 💻📊 Her diverse roles reflect her commitment to advancing healthcare and policy through innovation. 🌟

Research Achievements and Contributions 📚🏆

Dr. Tiantian Zhang, a Youth Researcher at Fudan University’s School of Public Health, has made significant contributions to healthcare management research. She has co-authored 9 policy briefs, receiving positive feedback from top political leaders, including members of the Central Political Bureau. 👩‍🔬✨ She has led a National Natural Science Foundation Youth Project and 7 provincial projects, while also contributing to major national R&D initiatives. Her research includes 37 published papers, 8 of which are in high-impact journals (SCI/SSCI, JCR-Q1), with a total impact factor of 68.5. 📝📊 Dr. Zhang has received multiple prestigious awards, including the Shanghai Decision-Making Advisory Research Awards and the Shanghai Youth Medal. 🏅

Academic Positions and Editorial Roles 📚🌟

Dr. Tiantian Zhang holds several prestigious academic roles. She is a Youth Elite Talent for the Shanghai Municipal Government Decision-Making Consulting Research Base (2024–2026) and an expert in Shanghai’s healthcare reform (2022–2025). 🏅 She serves on the Youth Committee of the Shanghai Medical Association’s Health Management Branch and is a director of the Chinese Medicine Informatics Society. 🩺 Additionally, she contributes to several academic journals, including Chinese Hospital Management and Chinese Public Health Management, where she holds youth editorial board positions. ✍️ She is also involved in writing and editing key publications, including the fifth edition of Health Management and the Blue Book on Proactive Health and Healthy Aging. 📖

Research Focus

Dr. Tiantian Zhang’s research focuses on public health management, health policy, and health data science. She is particularly interested in the intersection of healthcare system development and technology for proactive health and aging. 🏥 Her work includes studies on health equity, air pollution, dyslipidemia, and disease prevention, and she frequently contributes to research on health disparities and socioeconomic factors affecting public health. 🌍 Additionally, she explores health management practices and decision-making frameworks for improving healthcare services, with a strong emphasis on government regulation and community-based health interventions. 📊

Publication Top Notes

Association of circadian syndrome with risk of hyperuricemia among middle-aged and older adults in China – 2025 🕰️,
Research on government regulation methods for the spatial layout of retail pharmacies – 2024 🏪
Prevalence of dyslipidemia and associated factors in sedentary occupational population from Shanghai – 2024 ⚖️,
Global Justice Index Report 2023 – 2024 🌍, Cited by: 2 📑.
Association of long-term exposure to air pollutants with sensory impairment in middle-aged and elderly adults – 2024 🌫️
Equity analysis of older adult resource allocation in China – 2024 💼
Development of an assessment tool for designated medical institutions in China – 2024 💻
Association of indoor solid fuel use and long-term exposure to ambient PM2.5 with sarcopenia in China – 2023 🌫️, Cited by: 10 📑.
Global Justice Index Report 2022 – 2023 🌍, Cited by: 7 📑.

Miguel Virseda-Chamorro | Medicine and Dentistry | Best Researcher Award

Posted on 22/10/202422/10/2024 by ScienceFather

Dr. Miguel Virseda-Chamorro | Medicine and Dentistry | Best Researcher Award

Dr. Miguel Virseda-Chamorro, Hospital Nacional de parapléjicos, Spain

Dr. Miguel Virseda-Chamorro is a distinguished urologist with extensive expertise in urodynamics and pelvic floor disorders. He earned his MD from the University of Valencia in 1981 and specialized in Urology at Gómez Ulla Hospital in 1990. He holds a PhD, awarded cum laude in 1992, and completed further education in Health Sciences Statistics. Dr. Virseda is a Fellow of the European Board of Urology and has contributed to major scientific journals. Recognized with several prestigious awards, his research has impacted functional urology and neurogenic bladder treatment. He is fluent in multiple languages and an active member of several urological societies. 🏥🧬📊

Publication Profile

Scopus

Orcid

Academic Formation and Specializations

Dr. Virseda-Chamorro has an impressive academic trajectory, beginning with a Licenciatura in Medicine and Surgery from the University of Valencia (1981) and multiple specialized courses in Urology and Medical Aeronautics. He has also pursued advanced degrees, including a Master in Health Sciences Design and Statistics (2001), which supports his clinical research. His PhD in Urology, awarded with distinction, further underscores his expertise in the field.

Awards and Distinctions

His outstanding contributions have been recognized through several prestigious awards, such as the Best Doctoral Thesis Awards (1992, 1995), and multiple honors from the Spanish Urology Association for his groundbreaking research. These recognitions validate his impact on the field of urology, particularly in areas like urodynamic models and pelvic prolapse treatment.

Teaching and Clinical Trials

Dr. Virseda-Chamorro has also made significant contributions to medical education, leading various courses on pelvic floor treatment and urodynamic pediatric pathologies. His participation in numerous clinical trials, such as evaluating the efficacy of beta-3 agonists for overactive bladder, shows his ongoing commitment to advancing medical knowledge and patient care.

Conclusion

Dr. Miguel Virseda-Chamorro’s rich academic background, clinical expertise, significant research contributions, and numerous honors make him an ideal candidate for the Best Researcher Award. His dedication to both clinical practice and advancing scientific understanding in urology highlights his qualification for this prestigious recognition.

Umama Umar | Health Professions | Best Researcher Award

Posted on 10/09/202410/09/2024 by ScienceFather

Umama Umar | Health Professions | Best Researcher Award

Dr Umama Umar, Faisal Institute of Health Sciences Faisalabad, Pakistan

Dr. Umama Umar appears to be a suitable candidate for the Best Researcher Award in the field of physiotherapy, based on her academic achievements, research contributions, and practical experience. Here’s an assessment of her qualifications:

Publication profile

Orcid

Research & Publications

Dr. Umar’s publications focus on critical topics in physiotherapy, particularly preoperative respiratory muscle training, prehabilitation, and postoperative outcomes. Her work, including international journal articles and a research poster presented at conferences, reflects a strong contribution to clinical research aimed at improving patient outcomes in surgery, which aligns with the requirements for this award.

Practical Experience

Her experience as an independent physiotherapist, clinical intern, and previous role at Saad Medical Complex highlights her dedication to applying her research findings in clinical settings, enhancing her credibility in the physiotherapy domain.

Education & Certifications

Dr. Umar’s educational background in Doctor of Physical Therapy and further specialization through the BCTP course (accredited by London) strengthens her profile as a highly qualified researcher. Additional certifications in manual therapy and disaster response complement her academic credentials.

Conclusion

Given her research contributions, practical experience, and strong academic background, Dr. Umar’s application would be compelling for the Best Researcher Award, especially within the field of physiotherapy.

Publication top notes

Effects of preoperative respiratory muscle training for improvement of postoperative health related quality of life in mitral valve replacement patients

<b>COMPARISON OF RESPIRATORY PREHABILITATION FOR IMPROVEMENT OF POSTSURGERY OUTCOMES IN MITRAL VALVE PATIENTS </b>

khadijeh kalanfarmanfarma | Health Professions Award | Best Researcher Award

Posted on 06/09/202406/09/2024 by ScienceFather

Dr. khadijeh kalanfarmanfarma | Health Professions Award | Best Researcher Award

Dr. khadijeh kalanfarmanfarma, Kashan University of Medical Sciences, Kashan, Iran

Dr. Khadijeh Kalan Farmanfarma (born April 24, 1978) holds a PhD in Epidemiology and an M.Sc. in Health Education and Promotion. She has been recognized as a top researcher at both the national and university levels, notably at Zahedan University of Medical Sciences. Dr. Farmanfarma has contributed to over 20 high-impact publications, focusing on cancer epidemiology, metabolic syndrome, and public health. She is also a co-author of an eBook on the Renin-Angiotensin System and its role in diseases. Her research has earned her awards and recognition both nationally and internationally. 📚🌍🔬

Publication profile

Scopus

Google Scholar

Academic Background 🧠

Dr. Khadijeh Kalan Farmanfarma holds a PhD in Epidemiology and an M.Sc. in Health Education and Health Promotion. Her solid academic foundation is supported by multiple recognitions at the doctoral and master’s levels. Her focus on epidemiological research is crucial, particularly during global health challenges like COVID-19.

Research Contributions 📚

Dr. Farmanfarma has an impressive body of work, with more than 25 published research articles across Q1 to Q3 journals. Some highlights include:

COVID-19 Research: Her studies on the impact of COVID-19, especially on domestic violence and illness anxiety, show her commitment to addressing emerging public health issues.

Metabolic Syndrome & Cancer Epidemiology: Dr. Farmanfarma has published meta-analyses on metabolic syndrome and various cancers, which have gained significant attention in high-impact journals like Diabetes & Metabolic Syndrome: Clinical Research & Reviews (IF: 10.0, Q1).

Chronic Diseases & Breast Cancer Prevention: Her focus on chronic diseases and breast cancer prevention demonstrates her dedication to improving population health.

Recognitions 🏆

Dr. Farmanfarma’s accolades include being named the Top National Researcher and Top Researcher at Zahedan University of Medical Sciences multiple times, which speaks to her consistent excellence in research.

Publication Top Notes

📚 Prevalence of metabolic syndrome in Middle-East countries: Meta-analysis of cross-sectional studies – Cited by: 248 (2018)
📚 Prevalence of metabolic syndrome in Iran: A meta-analysis of 69 studies – Cited by: 149 (2019)
🧠 Brain cancer in the world: An epidemiological review – Cited by: 79 (2019)
🎗️ Improving Breast Cancer Preventive Behavior among Female Medical Staff: Educational Intervention – Cited by: 59 (2014)
📊 Epidemiologic study of gastric cancer in Iran: A systematic review – Cited by: 51 (2020)
📈 Prevalence of type 2 diabetes in Middle-East: Systematic review & meta-analysis – Cited by: 47 (2020)
🎗️ Effect of education on preventive behaviors of breast cancer in female teachers – Cited by: 35 (2014)
🩺 Study of breast cancer knowledge, attitude, and preventive behaviors in Yazd, Iran – Cited by: 22 (2017)
📊 Prevalence and trend of metabolic syndrome in South-East Iran – Cited by: 21 (2020)
🧬 Testicular cancer in the world: An epidemiological review – Cited by: 20 (2018)

Conclusion 📝

With her extensive research output, recognitions, and focus on significant public health issues, Dr. Khadijeh Kalan Farmanfarma is a strong candidate for the Research for Best Researcher Award. Her diverse and impactful research contributions in epidemiology, particularly in chronic diseases and cancer, reflect a distinguished career deserving of recognition.

Cristina Papayannidis | Medicine and Dentistry | Best Researcher Award

Posted on 23/08/202423/08/2024 by ScienceFather

Cristina Papayannidis | Medicine and Dentistry | Best Researcher Award

Dr Cristina Papayannidis, IRCCS, Azienda Ospedaliero Universitaria S.Orsola Malpighi, Bologna, Italy, Italy

Dr. Cristina Papayannidis appears to be an outstanding candidate for the Best Researcher Award based on several key criteria:

Publication profile

scopus

Extensive Experience

Dr. Papayannidis has been deeply involved in clinical research and patient care in hematology since her early career. Her role as Dirigente Medico Ematologia at IRCCS Azienda Ospedaliero Universitaria di Bologna highlights her leadership in AML and ALL clinical trials.

High Research Output

She has authored over 130 publications and has been a principal or sub-investigator in more than 60 phase 1-3 clinical trials, showcasing her significant contributions to advancing hematology research.

Recognition and Influence

With an H-index of 34, she has made substantial impacts in her field. Her role as a speaker at over 300 national and international events, including prestigious conferences like ASH and EHA, underscores her influential presence in the hematological community.

Mentorship and Leadership

Her positions as a mentor in EHA Master Classes and member of various working groups demonstrate her commitment to guiding the next generation of researchers and shaping the future of hematology.

Professional Memberships

Memberships in esteemed organizations such as SIE, EHA, and AACR, and her role on the Hematological Malignancies Committee ESMO further reflect her prominent status and active participation in the scientific community.

Dr. Papayannidis’s extensive research experience, high publication volume, significant impact on clinical practice, and active involvement in mentorship and professional societies make her a highly suitable candidate for the Best Researcher Award.

Research focus

The research focus of the individuals associated with these articles centers on hematological malignancies and their management. They investigate advanced treatments and strategies for diseases like acute lymphoblastic leukemia (ALL), particularly in the context of drug therapies and stem cell transplantation. Key topics include evaluating the efficacy of ponatinib versus imatinib in treating Philadelphia chromosome-positive ALL, using ponatinib to prevent relapse after transplantation, and assessing the impact of inotuzumab ozogamicin on outcomes and complications in refractory cases. Their work contributes to improving therapeutic approaches and patient outcomes in hematology. 🩺💉🔬

Publication top notes

Managing Patients with Hypereosinophilic Syndrome: A Statement from the Italian Society of Allergy, Asthma, and Clinical Immunology (SIAAIC)

Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission †

Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease

Dan Yan | Medicine and Dentistry | Best Researcher Award

Posted on 10/06/202410/06/2024 by ScienceFather

Dan Yan | Medicine and Dentistry | Best Researcher Award

Prof Dan Yan,Beijing Friendship Hospital, Capital Medical University,China

Prof. Dan Yan, Ph.D., is a leading figure in clinical pharmacy and precision medicine at Beijing Institute of Clinical Pharmacy, China. 🌟 With a robust background in traditional Chinese medicine and a Ph.D. from Chengdu University, he specializes in intelligent molecular diagnosis and combined medication for chronic metabolic diseases. 🧬 His groundbreaking research focuses on optimizing diabetes treatment, particularly exploring multi-drug combinations and personalized therapies. As a prolific author and committee member of prestigious scientific organizations, Prof. Yan is dedicated to advancing healthcare through innovative research and evidence-based practices. 📚✨

Publication profile

Scopus

Education

Prof. Dan Yan pursued an extensive educational journey at Chengdu University of Traditional Chinese Medicine, culminating in a Ph.D. from 2004 to 2007. Prior to his doctoral studies, he obtained his Master of Science degree from the same institution between 2001 and 2004. Prof. Yan’s academic pursuits trace back to his undergraduate years, where he completed his Bachelor of Science degree from 1994 to 1998, laying the foundation for his subsequent advanced studies. His educational background reflects a dedicated commitment to traditional Chinese medicine, fostering a deep expertise in this field.

Research focus

Prof. Dan Yan’s research focuses on the intelligent molecular diagnosis and combined medication for chronic metabolic diseases, particularly pre-diabetes and type 2 diabetes. His work leverages multi-omics approaches, such as metabolomics, to enhance early diagnosis and personalized treatment strategies. He aims to optimize drug combinations from a broad range of hypoglycemic drugs, including traditional and novel therapies. This research not only addresses the declining efficacy of long-term metformin use but also integrates pharmacoeconomics and evidence-based medicine to improve clinical outcomes in diabetes care.

Publication top notes

Structural characterization of Astragalus polysaccharide-D1 and its improvement of low-dose metformin effect by enriching Staphylococcus lentus

A systematic review on the appropriate discounting rates for the economic evaluation of gene therapies: Whether a specific approach is justified to tackle the challenges?

Antibiotic combinations predicti on based on machine learning to multicentre clinical data and drug interaction correlation

Uncovering the key pharmacodynamic material basis and possible molecular mechanism of Xiaoke formulation improve insulin resistant through a comprehensive investigation

Rapid multichannel fluorescent probe assay for CYP450 inhibition screening and drug interaction monitoring

QALY-type preference and willingness-to-pay among end-of-life patients with cancer treatments: a pilot study using discrete choice experiment

β-Elemene in zedoary turmeric oil injection induces dyspnea by binding to hemoglobin and upregulating HIF-1α

Predicting coronary heart disease in Chinese diabetics using machine learning

Editorial: Benefits and risks of drug combination therapy for chronic metabolic diseases

Quality assessment and control of Shuanghuanglian Lyophilized Injection based on cell response spectrum

Erica Pietroluongo | Medicine | Young Scientist Award

Posted on 08/02/202408/02/2024 by ScienceFather

Dr. Erica Pietroluongo | Medicine | Young Scientist Award

Dr. Erica Pietroluongo, University of Naples Federico II, Italy

👩‍⚕️ Dr. Erica Pietroluongo is a dedicated oncologist and researcher based in Naples, Italy. With an MD from the University of Naples Federico II and ongoing PhD studies in Advanced Biomedical and Surgical Therapies, she specializes in medical oncology, particularly in rare tumors. Dr. Pietroluongo is actively involved in various professional societies, including the American Society of Clinical Oncology and the International Thymic Malignancy Working Group. Her research focuses on improving treatment personalization in breast cancer and investigating bioumoral determinants in SARS-Cov-2-infected patients with thymic epithelial tumors. She also contributes to teaching and training future medical professionals.

Publication Profile:

Scopus

Orcid

Education:

📚 Dr. Erica Pietroluongo pursued her passion for medicine at the University of Naples Federico II, where she earned her MD in Medicine. With a strong foundation in healthcare, she embarked on a journey of continuous learning, currently immersing herself in the realm of research as a PhD student in Advanced Biomedical and Surgical Therapies. Under the guidance of Prof. F Pane at the Department of Clinical Medicine and Surgery, University of Naples Federico II, she delves into cutting-edge studies. 🎓 Committed to advancing medical knowledge, Dr. Pietroluongo’s dual roles as a physician and researcher epitomize her dedication to enhancing patient care and outcomes.

Teaching and Training:

📝 Dr. Erica Pietroluongo is deeply committed to advancing her skills in clinical research and teaching methodologies. In April 2023, she participated in a Medical Writing Course organized by the Italian Society of Surgery in Campobasso, in collaboration with prestigious institutions like Springer Nature and the University of Naples Federico II. This course equipped her with essential writing skills vital for disseminating research findings effectively. Moreover, in June 2023, she further honed her expertise as an “Expert in Evaluation and Facilitation of Regional Oncology Networks” through a program facilitated by AGENAS, the National Agency for Health Regional Services. 🌟 These training initiatives underscore Dr. Pietroluongo’s commitment to enhancing her capabilities and contributing to the advancement of healthcare practices.

Research Focus:

🔍 Dr. Erica Pietroluongo’s research focus primarily revolves around two key areas: thymic epithelial tumors and breast cancer. In her studies on thymic epithelial tumors, she explores the impact of SARS-Cov-2 mRNA vaccines on patients’ immune responses and seroconversion. Additionally, she investigates the potential diagnostic role of miRNAs in breast cancer, particularly miRNA-27a and miRNA-128, packaged in extracellular vesicles. Her work not only sheds light on the immunological responses to COVID-19 vaccines in cancer patients but also aims to identify novel biomarkers for improved diagnosis and prognosis in breast cancer. Dr. Pietroluongo’s research contributes significantly to both oncology and immunology fields. 🎯

Publication Top Notes:

Serum biomarkers of inflammation and vascular damage upon SARS-Cov-2 mRNA vaccine in patients with thymic epithelial tumors

miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer

Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors

Immunocytometric analysis of patients with thymic epithelial tumors revealed that COVID-19 vaccine booster strongly enhanced the immune response

Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study